Cargando…

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis

BACKGROUND: Cardiac amyloidosis due to amyloid fibril deposition in the heart results in cardiomyopathy (CMP) with heart failure (HF) and/or conduction disturbances. Immunoglobulin light chain–related CMP (AL‐CMP) features rapidly progressive HF with an extremely poor prognosis compared with a CMP d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Komei, Essick, Eric E., Doros, Gheorghe, Tanriverdi, Kahraman, Connors, Lawreen H., Seldin, David C., Sam, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647258/
https://www.ncbi.nlm.nih.gov/pubmed/23537813
http://dx.doi.org/10.1161/JAHA.112.005868
_version_ 1782268703884181504
author Tanaka, Komei
Essick, Eric E.
Doros, Gheorghe
Tanriverdi, Kahraman
Connors, Lawreen H.
Seldin, David C.
Sam, Flora
author_facet Tanaka, Komei
Essick, Eric E.
Doros, Gheorghe
Tanriverdi, Kahraman
Connors, Lawreen H.
Seldin, David C.
Sam, Flora
author_sort Tanaka, Komei
collection PubMed
description BACKGROUND: Cardiac amyloidosis due to amyloid fibril deposition in the heart results in cardiomyopathy (CMP) with heart failure (HF) and/or conduction disturbances. Immunoglobulin light chain–related CMP (AL‐CMP) features rapidly progressive HF with an extremely poor prognosis compared with a CMP due to the deposition of mutant (ATTR) amyloidosis or wild‐type (senile systemic amyloidosis, SSA) transthyretin (TTR) proteins. Amyloid fibril deposition disrupts the myocardial extracellular matrix (ECM) homeostasis, which is partly regulated by matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). We therefore tested the hypothesis that circulating levels of MMPs and TIMPs in patients with AL‐CMP and TTR‐related CMP (TTR‐CMP) are dissimilar and indicative of cardiac amyloid disease type. METHODS AND RESULTS: Fifty AL‐CMP patients were compared with 50 TTR‐CMP patients (composed of 38 SSA and 12 ATTR patients). Clinical and laboratory evaluations including echocardiography were performed at the initial visit to our center and analyzed. Serum MMP‐2, MMP‐9, TIMP‐1, and TIMP‐2 levels were determined by ELISA. Compared with TTR‐CMP patients, AL‐CMP patients had higher levels of brain natriuretic peptide (BNP), troponin I (TnI), MMP‐2, TIMP‐1, and MMP‐2/TIMP‐2 ratio, despite less left ventricular (LV) hypertrophy and better preserved LV ejection fraction. Mortality was worse in AL‐CMP patients than in TTR‐CMP patients (log‐rank P<0.01). MMP‐2/TIMP‐2 plus BNP and TnI showed the highest discriminative ability for distinguishing AL‐CMP from TTR‐CMP. Female sex (HR, 2.343; P=0.049) and BNP (HR, 1.041; P<0.01) were predictors for mortality for all patients with cardiac amyloidoses. Only BNP was a predictor of death in AL‐CMP patients (HR, 1.090; P<0.01). There were no prognostic factors for all‐cause death in TTR‐CMP patients. CONCLUSIONS: Circulating concentrations of MMPs and TIMPs may be useful in differentiating patients with AL‐CMP from those with TTR‐CMP, resulting in earlier diagnostic vigilance, and may add prognostic information. In addition to an elevated BNP level, female sex increased the risk of death in patients with cardiac amyloidoses.
format Online
Article
Text
id pubmed-3647258
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-36472582013-05-08 Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis Tanaka, Komei Essick, Eric E. Doros, Gheorghe Tanriverdi, Kahraman Connors, Lawreen H. Seldin, David C. Sam, Flora J Am Heart Assoc Original Research BACKGROUND: Cardiac amyloidosis due to amyloid fibril deposition in the heart results in cardiomyopathy (CMP) with heart failure (HF) and/or conduction disturbances. Immunoglobulin light chain–related CMP (AL‐CMP) features rapidly progressive HF with an extremely poor prognosis compared with a CMP due to the deposition of mutant (ATTR) amyloidosis or wild‐type (senile systemic amyloidosis, SSA) transthyretin (TTR) proteins. Amyloid fibril deposition disrupts the myocardial extracellular matrix (ECM) homeostasis, which is partly regulated by matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). We therefore tested the hypothesis that circulating levels of MMPs and TIMPs in patients with AL‐CMP and TTR‐related CMP (TTR‐CMP) are dissimilar and indicative of cardiac amyloid disease type. METHODS AND RESULTS: Fifty AL‐CMP patients were compared with 50 TTR‐CMP patients (composed of 38 SSA and 12 ATTR patients). Clinical and laboratory evaluations including echocardiography were performed at the initial visit to our center and analyzed. Serum MMP‐2, MMP‐9, TIMP‐1, and TIMP‐2 levels were determined by ELISA. Compared with TTR‐CMP patients, AL‐CMP patients had higher levels of brain natriuretic peptide (BNP), troponin I (TnI), MMP‐2, TIMP‐1, and MMP‐2/TIMP‐2 ratio, despite less left ventricular (LV) hypertrophy and better preserved LV ejection fraction. Mortality was worse in AL‐CMP patients than in TTR‐CMP patients (log‐rank P<0.01). MMP‐2/TIMP‐2 plus BNP and TnI showed the highest discriminative ability for distinguishing AL‐CMP from TTR‐CMP. Female sex (HR, 2.343; P=0.049) and BNP (HR, 1.041; P<0.01) were predictors for mortality for all patients with cardiac amyloidoses. Only BNP was a predictor of death in AL‐CMP patients (HR, 1.090; P<0.01). There were no prognostic factors for all‐cause death in TTR‐CMP patients. CONCLUSIONS: Circulating concentrations of MMPs and TIMPs may be useful in differentiating patients with AL‐CMP from those with TTR‐CMP, resulting in earlier diagnostic vigilance, and may add prognostic information. In addition to an elevated BNP level, female sex increased the risk of death in patients with cardiac amyloidoses. Blackwell Publishing Ltd 2013-04-24 /pmc/articles/PMC3647258/ /pubmed/23537813 http://dx.doi.org/10.1161/JAHA.112.005868 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Tanaka, Komei
Essick, Eric E.
Doros, Gheorghe
Tanriverdi, Kahraman
Connors, Lawreen H.
Seldin, David C.
Sam, Flora
Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title_full Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title_fullStr Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title_full_unstemmed Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title_short Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
title_sort circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647258/
https://www.ncbi.nlm.nih.gov/pubmed/23537813
http://dx.doi.org/10.1161/JAHA.112.005868
work_keys_str_mv AT tanakakomei circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT essickerice circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT dorosgheorghe circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT tanriverdikahraman circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT connorslawreenh circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT seldindavidc circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis
AT samflora circulatingmatrixmetalloproteinasesandtissueinhibitorsofmetalloproteinasesincardiacamyloidosis